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Abstract
Hypoglycaemia is the most frequent acute complication of diabetes, regardless
of the type of diabetes and the treatment method. Hormonally active tumours
of the pancreas, insulinomas, which belong to digestive tract neuroendocrine
tumours, constitute one of the less frequent causes of hypoglycaemia. This
paper presents a case of a 60-year-old type 2 diabetes patient with recurrent
hypoglycaemic events, in whom an insulin-secreting hepatic neuroendocrine
tumour was diagnosed. We suggest performing a diagnostic workup taking into
consideration insulinoma in patients with diabetes who experience frequent
otherwise inexplicable hypoglycaemic events, particularly when they recur
despite decreased dose or discontinuation of hypoglycaemic agents.
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Introduction
Hypoglycaemia is the most frequent acute complication of diabetes
regardless of the type of diabetes and the kind of therapy applied. Miller
et al. observed hypoglycaemia in 12% of patients treated by diet alone, in
16% of those treated with oral hypoglycaemic agents, and in as many as
30% of those using insulin [1]. The most frequent causes of hypoglycaemia
in patients with type 2 diabetes treated with oral hypoglycaemic agents
are: dose not adjusted for meals and physical activity, renal and/or hepatic
dysfunction, administration of certain drugs (β-blockers, ACE inhibitors,
sulphonamides) and alcohol consumption. Hormonally active tumour of
the pancreas, insulinoma, which belongs to digestive tract neuroendocrine
tumours (NET), is a very rare cause of hypoglycaemia. Such tumours, which
derive from pancreatic β cells of Langerhans and secrete insulin, are
insignificantly more frequent in women, with the reported incidence of 
4 cases per million subjects per year [2]. Insulinomas are usually benign,
occur as single tumours and are almost always located in the pancreas.
In a small percentage these tumours may be multifocal (about 10%,
particularly in the course of MEN1) or malignant (8-10%), resulting in local
infiltration and metastases to the liver and periaortic nodes [3]. The clinical
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picture is characterized by symptomatic hypo-
glycaemia associated with inappropriately increased
plasma insulin level [4]. In our study we present
a case of a 60-year-old patient with type 2 diabetes,
who  was  diagnosed  with  an  insulin-secreting
hepatic  neuroendocrine  tumour  of  aggressive
clinical course, manifesting with clinical features of
insulinoma:  recurrent  hypoglycaemic  events
impossible to be explained by treatment errors.
Case report
A60-year-old overweight female (BMI = 27 kg/m2)
with  type  2  diabetes  was  admitted  to  our
department in August 2007 due to recurrent epi-
sodes of hypoglycaemic episodes below 40 mg/dl,
that had occurred over several months prior to
admission. Diabetes was diagnosed in November
2006 based on fasting glucose levels over 125 mg/dl
and  postprandial  glycaemia  over  200  mg/dl
observed more than twice. Her past history included
chronic gastritis and duodenitis, cholecystolithiasis,
and ventricular arrhythmia treated with amio-
darone, which resulted in amiodarone-induced
thyrotoxicosis (2003). Diabetes had been managed
initially with a diabetic diet alone, but three months
prior  to  hospitalization  a small  dose  of  the
sulphonylurea (SM) derivative glimepiride was
added. As glimepiride was assumed to be a possible
cause of hypoglycaemia, it was discontinued and
metformin (MF) was administered. Nevertheless,
due to poor tolerance of metformin and elevated
glucose levels the patient still took SM tablets
occasionally.
Physical examination on admission revealed
blood pressure of 130/85 mmHg, pulse rate regular
85 beats/min, heart sounds were normal, the chest
was clinically clear and all peripheral pulses were
palpable.  Fundoscopy  showed  no  evidence  of
retinopathy. 
Following hospital admission oral hypoglycaemic
agents were discontinued and insulin was not
administered. Glucose levels ranged from 95 to 
133 mg/dl at fasting and before meals with marked
postprandial peaks up to 330 mg/dl. Glycosylated
haemoglobin (HbA1c) was 6.3%. Further inves-
tigational biochemical laboratory tests revealed
elevation  of  serum  alanine  aminotransferase 
(ALT) 112 U/l (ref. range: 10-36 U/l), aspartate
aminotransferase (AST) 99 U/l (ref. range: 10-30 U/l)
and  γ-glutamyl  transferase  (GGTP)  528  U/l
(ref. range: 5-39 U/l). There was also slight elevation
of alkaline phosphatase (ALP) 181 U/l (ref. range: 
42-141 U/l). Bilirubin levels were normal (0.75 mg/dl,
ref. range: 0.2-1.0 mg/dl) and serological testing
showed no evidence of hepatitis B and C. Moreover,
a slightly higher level of serum carcinoembryonic
antigen (CEA) 5.46 ng/ml (ref. range: to 3.4 ng/ml)
was observed. Renal function parameters and
serum electrolytes were within normal limits. Serum
thyroid hormones were normal and antithyroid
antibodies were not detected. The erythrocyte
sedimentation rate during the first hour (ESR) was
8 mm/h. The 72-h fasting test was performed and
failed to demonstrate hypoglycaemic episodes; the
serum insulin concentration was below 2.0 ﾵU/ml
(ref. range: 6-27 ﾵU/ml) at the end of the test.
Abdominal ultrasonography (USG) and com-
puted abdominal tomography (CT) showed an
extensive disintegrating hyperechogenic hepatic
mass of 100 ￗ 75 ￗ 85 mm in diameter. There was
evidence of modelling of the portal vein and bile
duct structure. There were also numerous focal
lesions up to 28 mm in the remaining parenchyma,
without hepatomegaly or pathological changes in
other abdominal organs or retroperitoneal space.
Awaiting further diagnostic workup, the patient was
asked to control occasional episodes of postprandial
hyperglycaemia with small doses of the fast acting
insulin  analogue  lispro  administered  subcuta-
neously. 
In September 2007 fine needle aspiration biopsy
(FNAB) of the liver was performed. Histopathology
revealed a neoplasm that consisted of cells of low
pleomorphism showing neuroendocrine origin.
Then, somatostatin (SST) receptor scintigraphy
(SRS) was performed with 99mTc-HYNIC-TOC and
SST receptor expression was demonstrated in the
liver focal lesions without metastatic spread to
other organs.
During the next hospitalization, in October 2007,
despite insulin discontinuation, two incidents of
hypoglycaemia below 40 mg/dl were observed; in
one case insulin level was 289 ﾵU/ml. Moreover,
elevated serum levels of chromogranin A (CgA)
506.5 U/l (ref. range: 2-18 U/l), human chorionic
gonadotrophin-β subunit (BhCG) 10.66 U/l (ref.
range: < 6.0 U/l) and urinary 5-hydroxy indolic acetic
acid (5-HIAA) 26.3 mg/24 h (ref. range: 0.7-8.0 mg/
24 h) were detected. The 24 h secretion patterns of
adrenocorticotropin and cortisol and the urinary
concentrations  of  adrenaline,  noradrenaline,
dopamine,  vanillylmandelic  acid  and  serum 
α-fetoprotein were normal. Despite the use of
several  diagnostic  methods  (abdominal  USG,
abdominal  and  thoracic  CT,  colonoscopy  and
gastroscopy) no obvious pancreatic lesion was
recognized. In view of the advanced stage of the
hepatic tumour, further investigation, such as
endoscopic ultrasound (EUS), was abandoned. After
surgical consultation the patient was disqualified
from surgical treatment owing to the progression of
the neoplastic process and the location of the main
tumour mass in a non-operable site (liver hilus). 
Long-acting SST analogue (Sandostatin LAR
20 mg per month) in 3-month therapy resulted in
near  normal  glucose  levels  and  diminished
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incidence of hypoglycaemia, followed by reduction
of CgA level (73.3 U/l). Unfortunately, abdominal CT
revealed neoplasm progression: hepatomegaly to
118 ￗ 97 ￗ 132 mm with evidence of necrosis,
numerous focal lesions up to 28 mm, with the
involvement of para-aortal and mesenteric lymph
nodes. As the neoplasm progressed, three cycles of
radioisotope therapy with Y-90 DOTA TATE with atotal
dose of 3.35 GBq were applied and further treatment
with long-acting somatostatin analogue (Sandostatin
LAR 30 mg per month) was continued. Nevertheless,
the  patient  experienced  severe  hypoglycaemic
incidents. Laboratory evaluation during one of the
documented episodes showed low plasma glucose
of 29 mg/dl, elevated insulin of 136 ﾵU/ml (ref. 
range: 2.6-24.9 ﾵU/ml), and C-peptide of 13.3 ng/ml 
(ref. range: 0.7-1.3 ng/ml). After starting diazoxide
therapy, she manifested no symptoms of hypo-
glycaemia, but her blood glucose levels increased. 
Six  months  after  radioisotope  therapy,  the
patient is being treated with insulin lispro (6-8 units
with each meal), NPH insulin 12 units at night, long-
acting  SST  analogue  (30 mg  per  month)  and
diazoxide (50 mg every other day). She has no
symptoms of hypoglycaemia and her blood glucose
levels on fasting range from 116 to 158 mg/dl with
postprandial peaks to 186 mg/dl. 
Discussion
Hypoglycaemia  is  a frequent  and  usually
unavoidable phenomenon in patients with type 2
diabetes, particularly those treated with drugs that
increase secretion of endogenous insulin. Although
in type 2 diabetes impairment in insulin secretion
and/or decrease in tissue sensitivity to its activity
(insulin resistance) are observed, excessive physical
exercise or dietary errors may still result in transient
decrease  of  glucose levels.  Discontinuation  of
glimepiride (sulphonylurea) at the beginning of the
diagnostic process was accompanied by diabetic
education covering diet, physical activity and health-
oriented behaviour. The patient’s stable weight was
not characteristic of insulinoma either, weight gain
being observed in almost half of patients [4].
When  therapy-related  hypoglycaemia  was
excluded, other potential causes such as reactive
hypoglycaemia,  decreased  hormone  secretion
(hypothyroidism,  adrenal  hypofunction),  renal
insufficiency, gastrointestinal tract diseases or drug
interactions were taken into consideration. 
In  such  circumstances  incidents  of  sudden
decrease of plasma glucose level suggested ectopic
insulin secretion. The 72-h fasting test constitutes
the  golden  standard  in  the  diagnosis  of
hypoglycaemia. In our patient low blood glucose
level with inappropriately high insulin level was
observed  only  during  the  second  fasting  test
performed after 2 months of observation.
A hepatic  NET  tumour  of  low  grade  of
differentiation was diagnosed on the basis of liver
biopsy. Its clinical features of insulinoma resulted
from  excessive  insulin  secretion,  leading  to
recurrent hypoglycaemic episodes.
Surgical treatment involving both the main
tumour,  usually  located  in  the  pancreas,  and
metastases is the therapy of choice in insulinoma.
In the discussed case, diagnostic imaging using
conventional methods, CT and USG, failed to show
a pancreatic  tumour,  which  is  in  accordance 
with the literature data assessing their sensitivity
in insulinoma diagnostics at 27-30% [5]. Moreover,
SRS – a very sensitive method for the demon-
stration of receptor-positive tumours and their
metastases – did not visualize any extra-hepatic
manifestation. Primary hepatic neuro-endocrine
tumours are extremely rare and there are only a few
well documented similar cases [6]. 
Due to the advanced neoplastic process at the
time of diagnosis and the disadvantageous location
of the main tumour mass, surgical treatment was
excluded. 
SST  analogues  play  the  main  role  in  the
pharmacotherapy of hormonally functioning NET,
because they usually enable clinical stabilization
and resolution of symptoms related to increased
hormone secretion [7]. There was evidence of
insulinoma  metastases  regression  during  that
treatment. Efficacy of SST analogues is diminished
in about 30% of insulinoma cases not presenting
SST receptors sst2 and sst5 [8]. Moreover, SST
analogues may induce acute hypoglycaemia [9]. 
In our patient, the therapy with a long-acting
SST analogue was preceded by confirmation of the
presence of SST receptors and by a clinical test with
a short-acting SST analogue. The reduction in
frequency of incidence of hypoglycaemia with
diminished  plasma  levels  of  CgA  indirectly
confirmed the therapy’s efficacy. 
In the described case glycaemic control was an
important issue in the course of diabetes. Due to
the tendency to postprandial hyperglycaemia and
coexisting hypoglycaemic episodes, lispro therapy
was introduced in a dose adjusted to current
glycaemia.  The  choice  of  rapid-acting  insulin
analogue was determined by its beneficial short
action  time  and  decrease  of  hypoglycaemia
incidence frequency compared to human insulins.
Additionally, diazoxide was introduced at alater stage.
According to literature reports this agent by lowering
insulin secretion enables good glycaemic control in
59% and diminishes incidence of hypoglycaemia in
38% of patients with insulinoma [10].
In  conclusion,  there  are  few  reports  of  the
coexistence of insulinoma and type 2 diabetes. 
In American studies diabetes was recognized only
in  1  patient  among  313  hospitalised  due  to
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insulinoma, which was significantly less frequent
than the occurrence of this tumour in the whole
population [11].
However,  diagnostic  workup  taking  into
consideration insulinoma in patients with diabetes
should be considered in cases of recurring and
inexplicable hypoglycaemic events, particularly
when common causes related to medication and
concurrent diseases have been excluded.
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